{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:49:18Z","timestamp":1774313358159,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00262-018-2197-x","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T07:30:57Z","timestamp":1530603057000},"page":"1371-1380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette\u2013Guerin for patients with non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2720-9640","authenticated-orcid":false,"given":"Wataru","family":"Obara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renpei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Mimata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"2197_CR1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette\u2013Guerin in the treatment of superficial bladder tumors. J Urol 116:180\u2013183","journal-title":"J Urol"},{"key":"2197_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou Redorta J, Roupret M (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64:639\u2013653","journal-title":"Eur Urol"},{"key":"2197_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2009.11.023","volume":"57","author":"P Gontero","year":"2010","unstructured":"Gontero P, Bohle A, Malmstrom PU, O\u2019Donnell MA, Oderda M, Sylvester R, Witjes F (2010) The role of bacillus Calmette\u2013Guerin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 57:410\u2013429","journal-title":"Eur Urol"},{"key":"2197_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","volume":"179","author":"HW Herr","year":"2008","unstructured":"Herr HW, Morales A (2008) History of bacillus Calmette\u2013Guerin and bladder cancer: an immunotherapy success story. J Urol 179:53\u201356","journal-title":"J Urol"},{"key":"2197_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","volume":"61","author":"TC Zuiverloon","year":"2012","unstructured":"Zuiverloon TC, Nieuweboer AJ, Vekony H, Kirkels WJ, Bangma CH, Zwarthoff EC (2012) Markers predicting response to bacillus Calmette\u2013Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61:128\u2013145","journal-title":"Eur Urol"},{"key":"2197_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","volume":"44","author":"AP van der Meijden","year":"2003","unstructured":"van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV (2003) Maintenance bacillus Calmette\u2013Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44:429\u2013434","journal-title":"Eur Urol"},{"key":"2197_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JA, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18:312\u2013322","journal-title":"Lancet Oncol"},{"key":"2197_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558\u2013562","journal-title":"Nature"},{"key":"2197_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015\u20131026","journal-title":"N Engl J Med"},{"key":"2197_CR10","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","volume":"35","author":"AB Apolo","year":"2017","unstructured":"Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL (2017) Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol 35:2117\u20132124","journal-title":"J Clin Oncol"},{"key":"2197_CR11","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O\u2019Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH (2016) Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34:3119\u20133125","journal-title":"J Clin Oncol"},{"key":"2197_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69\u201374","journal-title":"Science"},{"key":"2197_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.4049\/jimmunol.1500751","volume":"195","author":"DM Barrett","year":"2015","unstructured":"Barrett DM, Grupp SA, June CH (2015) Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J Immunol 195:755\u2013761","journal-title":"J Immunol"},{"key":"2197_CR14","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1158\/0008-5472.CAN-06-3748","volume":"67","author":"M Kanehira","year":"2007","unstructured":"Kanehira M, Katagiri T, Shimo A, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y (2007) Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Cancer Res 67:3276\u20133285","journal-title":"Cancer Res"},{"key":"2197_CR15","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1038\/sj.onc.1210466","volume":"26","author":"M Kanehira","year":"2007","unstructured":"Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y, Katagiri T (2007) Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 26:6448\u20136455","journal-title":"Oncogene"},{"key":"2197_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/jjco\/hys069","volume":"42","author":"W Obara","year":"2012","unstructured":"Obara W, Ohsawa R, Kanehira M, Takata R, Tsunoda T, Yoshida K, Takeda K, Katagiri T, Nakamura Y, Fujioka T (2012) Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol 42:591\u2013600","journal-title":"Jpn J Clin Oncol"},{"key":"2197_CR17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/annonc\/mdw675","volume":"28","author":"W Obara","year":"2017","unstructured":"Obara W, Eto M, Mimata H, Kohri K, Mitsuhata N, Miura I, Shuin T, Miki T, Koie T, Fujimoto H, Minami K, Enomoto Y, Nasu T, Yoshida T, Fuse H, Hara I, Kawaguchi K, Arimura A, Fujioka T (2017) A phase I\/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. Ann Oncol 28:798\u2013803","journal-title":"Ann Oncol"},{"key":"2197_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1399-0039.1996.tb02520.x","volume":"47","author":"Y Date","year":"1996","unstructured":"Date Y, Kimura A, Kato H, Sasazuki T (1996) DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens 47:93\u2013101","journal-title":"Tissue Antigens"},{"key":"2197_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466\u2013475 (discussion 475\u2013477)","journal-title":"Eur Urol"},{"key":"2197_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/1479-5876-10-141","volume":"10","author":"K Kono","year":"2012","unstructured":"Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R, Matsubara H, Ohira M, Baba H, Natsugoe S, Kitano S, Takeda K, Yoshida K, Tsunoda T, Nakamura Y (2012) Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 10:141","journal-title":"J Transl Med"},{"key":"2197_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/156800911793743664","volume":"11","author":"S Cecco","year":"2011","unstructured":"Cecco S, Muraro E, Giacomin E, Martorelli D, Lazzarini R, Baldo P, Dolcetti R (2011) Cancer vaccines in phase II\/III clinical trials: state of the art and future perspectives. Curr Cancer Drug Targets 11:85\u2013102","journal-title":"Curr Cancer Drug Targets"},{"key":"2197_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrd3500","volume":"10","author":"WJ Lesterhuis","year":"2011","unstructured":"Lesterhuis WJ, Haanen JB, Punt CJ (2011) Cancer immunotherapy\u2013revisited. Nat Rev Drug Discov 10:591\u2013600","journal-title":"Nat Rev Drug Discov"},{"key":"2197_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","volume":"57","author":"M Duchek","year":"2010","unstructured":"Duchek M, Johansson R, Jahnson S, Mestad O, Hellstrom P, Hellsten S, Malmstrom PU (2010) Bacillus Calmette\u2013Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol 57:25\u201331","journal-title":"Eur Urol"},{"key":"2197_CR24","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette\u2013Guerin, and bacillus Calmette\u2013Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57:766\u2013773","journal-title":"Eur Urol"},{"key":"2197_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00002371-200203000-00001","volume":"25","author":"U Keilholz","year":"2002","unstructured":"Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97\u2013138","journal-title":"J Immunother"},{"key":"2197_CR26","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1158\/1078-0432.CCR-10-2234","volume":"17","author":"LH Butterfield","year":"2011","unstructured":"Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Hakansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML (2011) Recommendations from the iSBTc-SITC\/FDA\/NCI workshop on immunotherapy biomarkers. Clin Cancer Res 17:3064\u20133076","journal-title":"Clin Cancer Res"},{"key":"2197_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/1479-5876-9-155","volume":"9","author":"D Bedognetti","year":"2011","unstructured":"Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, Tomei S, Fox BA, Gajewski TF, Marincola FM, Butterfield LH (2011) SITC\/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools\u2014a compass in the land of biomarker discovery. J Transl Med 9:155","journal-title":"J Transl Med"},{"key":"2197_CR28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1349-7006.2009.01416.x","volume":"101","author":"M Miyazawa","year":"2010","unstructured":"Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, Nakamura Y, Yamaue H (2010) Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 101:433\u2013439","journal-title":"Cancer Sci"},{"key":"2197_CR29","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1111\/j.1349-7006.2009.01329.x","volume":"100","author":"I Homma","year":"2009","unstructured":"Homma I, Kitamura H, Torigoe T, Tanaka T, Sato E, Hirohashi Y, Masumori N, Sato N, Tsukamoto T (2009) Human leukocyte antigen class I down-regulation in muscle-invasive bladder cancer: its association with clinical characteristics and survival after cystectomy. Cancer Sci 100:2331\u20132334","journal-title":"Cancer Sci"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-018-2197-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2197-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2197-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:11:04Z","timestamp":1659057064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-018-2197-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["2197"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2197-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"19 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Y. Nakamura reports receiving a commercial research grant from and has ownership interest (including patents) in OncoTherapy Science, Inc. No potential conflicts of interest were disclosed by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board at each hospital and was registered with Clinical Trials.gov as NCT 00633204. This study was carried out according to the Helsinki declaration on experimentation on human subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}